Bryostatin Compound Synthesis Through Convergent Fragment Coupling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing bryostatin compounds, such as bryostatin 1, are inefficient, requiring numerous synthetic steps and low overall yields, making it difficult to produce sufficient quantities for clinical applications.
Innovation Solution
A low-step, scalable method for synthesizing bryostatin compounds, including bryostatin 1, from commercially available materials, enabling production in multi-gram quantities and facilitating the synthesis of various analogs and prodrug forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional chemical synthesis methods are used to prepare bryostatin 1, then the compound can be produced, but the synthesis requires 37-90 steps with low overall yield (1.1% for the 57-step Keck synthesis)
Solution Approach 1:
The synthesis is divided into two independent hemispherical fragments (Northern and Southern) that can be prepared separately and then coupled together. This segmentation reduces the linear sequence length from 57 steps to 29 steps by allowing parallel preparation of fragments, directly addressing the complexity issue while maintaining productivity
Solution Approach 2:
The patent transitions from a linear sequential synthesis approach to a convergent approach where two hemispheres are prepared independently and joined. This dimensional change in synthesis strategy reduces the number of steps and improves overall yield by eliminating redundant operations and enabling parallel processing
2Quantity of substance
If conventional synthesis methods are used, then bryostatin 1 can be produced in trace amounts (0.00014% yield from natural isolation), but sufficient quantities for clinical trials cannot be obtained
Solution Approach 1:
The patent employs asymmetric allylation reactions that create chiral centers with high stereoselectivity, allowing the synthesis to proceed efficiently toward the desired enantiomer without requiring complex resolution processes. This self-service approach to stereocontrol significantly improves both yield and quantity production
Solution Approach 2:
The patent optimizes reaction parameters including stoichiometry, temperature, solvent selection, and catalyst loading to maximize yield at each step. By carefully controlling these parameters, the synthesis achieves high overall yield (greater than 10% improvement over conventional methods) while producing sufficient quantities for clinical applications
3Ease of manufacture
If the Keck synthesis method is used, then bryostatin 1 can be prepared, but the overall yield is low (1.1%) and the process is not scalable
Solution Approach 1:
By segmenting the synthesis into two hemispherical fragments that can be prepared independently and coupled together, the patent enables scalability. Each fragment can be optimized and produced at different scales, and the coupling step consolidates the two halves into the final product, significantly improving ease of manufacture and reducing material waste
Solution Approach 2:
The patent recovers and reuses certain reagents and intermediates throughout the synthesis process, particularly in the coupling of hemispherical fragments. This recovery strategy reduces material loss and lowers overall production costs, making the process economically viable for large-scale clinical supply
Data Source
AI summary
Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.